Histology
Carcinoma of Unknown Primary
CI-CAN-00002109Explore in graph →
4,156 active trials54 approved drugs532 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00002109Explore in graph →
Clinical trials
14,232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,893)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01498757 | Genome-wide Association Study | withdrawn | — | 0 | Samsung Medical CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT03300401 | Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT03388931 |
| Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx |
| withdrawn |
| Phase 4 |
| 0 |
| University of FloridaOTHER |
| 1 |
| May 13, 2019 |
| clinicaltrials |
| NCT02817607 | Study to Assess Breast Sensation Before and After Breast Cancer Treatment | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT03775707 | Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria | withdrawn | Phase 2 | 0 | Shi MingOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03780634 | HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03803254 | HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03744247 | Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC | withdrawn | Phase 3 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT03782831 | TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT03791918 | Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria | withdrawn | Phase 3 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT03644589 | Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 | Apr 26, 2019 | clinicaltrials |
| NCT03325465 | Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT02341170 | HS-PCI in Locally Advanced Adenocarcinoma of the Lung(HIPPO-S) | withdrawn | N/A | 0 | Universitätsmedizin MannheimOTHER | 0 | Apr 17, 2019 | clinicaltrials |
| NCT03746249 | Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03114280 | Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)(PICH) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Antoine LacassagneOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT02610920 | Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection | withdrawn | Early Phase 1 | 0 | Columbia UniversityOTHER | 0 | Mar 26, 2019 | clinicaltrials |
| NCT02542137 | Abscopal Effect for Metastatic Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 0 | Mar 21, 2019 | clinicaltrials |
| NCT00784329 | Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway Disease | withdrawn | N/A | 0 | Lahey ClinicOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT02867332 | PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma. | withdrawn | Phase 1 | 0 | Peking UniversityOTHER | 0 | Mar 6, 2019 | clinicaltrials |
| NCT02050009 | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT02891733 | Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung Adenocarcinomas(NTS) | withdrawn | — | 0 | Fondation Hôpital Saint-JosephOTHER | 0 | Feb 4, 2019 | clinicaltrials |
| NCT03346304 | Photodynamic Therapy for the Prevention of Lung Cancer(PEARL) | withdrawn | Phase 2 / Phase 3 | 0 | University College, LondonOTHER | 0 | Feb 1, 2019 | clinicaltrials |
| NCT02570529 | Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy | withdrawn | Phase 4 | 0 | Yonsei UniversityOTHER | 0 | Jan 29, 2019 | clinicaltrials |
| NCT03147196 | Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 22, 2019 | clinicaltrials |
| NCT03323710 | Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Military Institute od Medicine National Research InstituteOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT03693573 | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 0 | Nov 15, 2018 | clinicaltrials |
| NCT03226236 | Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC(RENALVax-2) | withdrawn | Phase 2 | 0 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 9, 2018 | clinicaltrials |
| NCT02599909 | Gut Microbiota in People With Hepatocellular Carcinoma (HCC) | withdrawn | — | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 20, 2018 | clinicaltrials |
| NCT03345225 | A Clinical Study of Precision TACE (P-TACE) With Surefire | withdrawn | N/A | 0 | University of MiamiOTHER | 1 | Sep 11, 2018 | clinicaltrials |
| NCT02750033 | Intraoperative Margin Assessment During Mohs Surgery | withdrawn | — | 0 | Seton Healthcare FamilyOTHER | 0 | Aug 20, 2018 | clinicaltrials |
| NCT01642095 | Studying Biomarkers in Samples From Younger Patients With Kidney Cancer | withdrawn | — | 0 | Children's Oncology GroupNETWORK | 1 | Aug 7, 2018 | clinicaltrials |
| NCT00488384 | Acitretin Plasma Levels Under Hemodialysis | withdrawn | Phase 4 | 0 | Günther HofbauerOTHER | 1 | Jul 19, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT02943603 | A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach | withdrawn | Phase 2 | 0 | Weijing Sun, MD, FACPOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT02168179 | KeraStat Skin Therapy in Treating Radiation Dermatitis in Patients With Newly Diagnosed Stage 0-IIIA Breast Cancer | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT03045393 | Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC(IMGN853) | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01325753 | Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Jul 3, 2018 | clinicaltrials |
| NCT03168152 | Randomized Trial Comparing Stereotactic Body Radiation Therapy to Microwave Ablation for the Treatment of Localized Hepatocellular Carcinoma | withdrawn | N/A | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 25, 2018 | clinicaltrials |
| NCT03149159 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | withdrawn | Phase 2 | 0 | Medical University of South CarolinaOTHER | 1 | Jun 18, 2018 | clinicaltrials |
| NCT02702960 | Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT02250404 | Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide | withdrawn | — | 0 | University of Southern CaliforniaOTHER | 1 | May 25, 2018 | clinicaltrials |
| NCT02149771 | Combination Treatment for Advanced Liver Cancer | withdrawn | Phase 3 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 19, 2018 | clinicaltrials |
| NCT02962804 | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | University of Kansas Medical CenterOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01710293 | Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis(PACT CREATE 3) | withdrawn | N/A | 0 | VA Office of Research and DevelopmentFED | 1 | Feb 26, 2018 | clinicaltrials |
| NCT02496832 | A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo | withdrawn | N/A | 0 | University Health Network, TorontoOTHER | 0 | Feb 19, 2018 | clinicaltrials |
| NCT01956864 | Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer | withdrawn | Phase 1 | 0 | Johns Hopkins UniversityOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT02908165 | Randomized Phase II Trial of Chemoembolization and Sorafenib | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT02993991 | Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity(PRIMED-001) | withdrawn | Phase 1 | 0 | University Health Network, TorontoOTHER | 1 | Dec 29, 2017 | clinicaltrials |
Data updated 23 days agoSource updated May 21, 2019source: clinicaltrials